Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tesofensine on Weight Reduction in Patients With Obesity.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Obese patients with 30 kg/m² ≤ BMI ≤ 40 kg/m²~* Males and females 18 to 65 years of age, extremes included~* Patients continuously receiving diet therapy as well as instructions on exercise at least for 2 weeks run-in, who during the run-in before randomization do not gain weight (\< 2 kg)~* Females of childbearing potential must be non-pregnant and use safe contraceptive methods (the pill, IUD or surgically sterilized)~* Patients should be able to comply with study procedures~* Smoking habits should have been stable for at least 2 months~* Patients giving written informed consent~Exclusion Criteria:~* Use of prescription medication as listed~* Positive serum pregnancy test for women of childbearing potential~* Pregnant or lactating women, or women who are planning to become pregnant within the next 8 months~* Patients with specific diseases interfering with their metabolism e.g. untreated myxoedema, Cushing's syndrome, Type 1 diabetes mellitus, significant neurological or psychiatric illness such as epilepsy, schizophrenia, depression, eating disorders such as bulimia.~* Patients with Type 2 diabetes mellitus are ineligible unless anti-diabetic medication was not deemed necessary by the investigator and fasting (venous or arterialized capillary full blood from finger or ear) blood glucose \> 6.1 mmol/l at screening. Re-test is allowed if first measure is above inclusion value. The corresponding exclusion criteria for plasma glucose is 7.0 mmol/l~* Patients currently (within the past 2 months) known to abuse or to be dependent on any drug, including alcohol (weekly consumption \> 21 units of alcohol (men) or \>14 units of alcohol (women))~* Hepatic or renal dysfunction (ASAT and/or ALAT \> 2 x ULN and creatinine clearance \< 30 mL/min estimated by central laboratory using Cockcroft and Gault formula, respectively)~* Known untreated hypercholesterolaemia (\> 7 mmol/l). Patients with well regulated cholesterol using drugs for hypercholesterolaemia are allowed inclusion~* Known untreated hypertriglyceridaemia (\> 3 mmol/l). Patients with well regulated triglyceride levels using drugs for hypertriglyceridaemia are allowed inclusion~* Drug treated thyroid diseases (well substituted hypothyroidism is allowed)~* Patients who suffer from hyperthyroid disease are not allowed in the study, even though they may be well treated by drugs~* Patients, who have recently diagnosed, not yet stable hypothyroid disease are not allowed in the study~* Patients who suffer from longstanding stable hypothyroid disease, well treated substitution are allowed to be included including hypothyroidism as a sequelae to definitive treatment of hyperthyroidism by surgery or radioactive iodine~* Malabsorptive intestinal disorders that can be assumed to affect the absorption of tesofensine~* Special diets (e.g., vegetarian, Atkins)~* Patients planning major changes in physical activity during the study to an extent that may interfere with the study outcome, as judged by the investigator~* Weight change of \> 3 kg within 2 months prior to screening~* Mental or psychiatric disorder based on medical history only~* Surgically treated obesity~* Patients with systemic infections or inflammatory diseases~* History or presence of significant cardiovascular disease such as heart failure, ischemic heart disease, stroke, transient ischemic attacks~* Significant abnormalities on the ECG. according to the investigators opinion. Additional exclusionary ECG values: QTcB \> 480 milliseconds (ms), PR interval \> 240 ms, QRS interval \> 120 ms~* Hypotension (i.e. supine systolic BP \< 90 mm Hg) and/or symptomatic orthostatic hypotension (clinical symptoms of orthostatic hypotension associated with a decline ≥ 20 mm Hg in systolic BP at one minute after standing compared with the previous supine systolic BP obtained after 5 minutes of quiet rest) at screening visit~* Uncontrolled hypertension (i.e. sitting diastolic BP ≥ 95 mm Hg and sitting systolic BP ≥ 155 mm Hg) despite treatment for \> 4 weeks prior to the screening visit as well as HR\>90 bpm~* Known HIV infection (no tests required)~* Serologic evidence of active hepatitis B and/or C~* History of cancer within the past 5 years, excluding treated basal cell carcinoma~* Clinically significant or potentially disabling eye disorder, including uncontrolled glaucoma~* Current treatment with medication with known ocular toxicity such as chloroquine and hydroxychloroquine is prohibited~* Patients previously treated with tesofensine~* Patients treated with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).